- Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
- Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT
- Cellectis publie ses résultats financiers du premier trimestre 2022
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
- Monthly information on share capital and company voting rights
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Cellectis annonce ses résultats financiers pour le premier trimestre 2022
- Cellectis to Report First Quarter 2022 Financial Results
- Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
- Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
More ▼
Key statistics
As of last trade Cellectis SA (ZVA:FRA) traded at 2.96, 7.96% above its 52-week low of 2.74, set on May 12, 2022.
52-week range
Markit short selling activity
Open | 2.96 |
---|---|
High | 2.96 |
Low | 2.96 |
Bid | 3.11 |
Offer | 3.15 |
Previous close | 2.98 |
Average volume | 116.40 |
---|---|
Shares outstanding | 45.48m |
Free float | 38.34m |
P/E (TTM) | -- |
Market cap | 134.85m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 15 minutes, as of May 17 2022 07:03 BST.
More ▼